For almost 40 years Randox has been at the forefront of diagnostics, leading the way with its disruptive technology and versatile product offering.
In January 2020, Randox was one of the first diagnostic companies to respond to the coronavirus pandemic, launching a molecular diagnostic test in just a few weeks.
To assist with winter testing strategies, a multiplex test capable of differentiating SARS-CoV-2 from nine other respiratory viruses including influenza is also available. Delivering a complete testing package for the diagnosis of COVID-19, a full range of quality control and external quality assessment solutions are also available.
With speed, accuracy and reliability at its core the diverse product range comprises third-party quality control solutions; RIQAS, the world’s largest EQA scheme; over 113 diagnostic reagents including many niche and superior performance assays; clinical chemistry analysers and patented biochip technology.
The revolutionary biochip is capable of simultaneously detecting hundreds of targets from a single patient sample. Complete patient profiling in this way facilitates faster patient testing, earlier diagnosis and improved patient pathways.
